BTI
BIB icon

Blue Trust Inc’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Blue Trust Inc’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33
Closed -$2K – 2309
2022
Q4 		$2K Hold
33
– – ﹤0.01% 1896
2022
Q3 		$2K Hold
33
– – ﹤0.01% 1755
2022
Q2 		$2K Buy
+33
New +$1.68K ﹤0.01% 1631

Other funds holding BIB

IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Blue Trust Inc's BIB Position: Q1 2023 in Review

Blue Trust Inc sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2023, closing a stake of 33 shares — an estimated $2K sold.

Blue Trust Inc first reported a position in BIB in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q4 2022. 24 funds tracked by Wall St. Rank hold BIB as of Q1 2023.

  • Blue Trust Inc reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Blue Trust Inc sold 33 ProShares Ultra NASDAQ Biotechnology shares in Q1 2023, an estimated $2K.
  • Blue Trust Inc first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2022 and held it in 3 quarters.
  • Blue Trust Inc's ProShares Ultra NASDAQ Biotechnology position peaked at $2K in Q4 2022.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2023.

Based on Blue Trust Inc's 13F filing for Q1 2023, filed 17 Apr 2023.